📣 VC round data is live. Check it out!

Rigel Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Rigel Pharmaceuticals and similar public comparables like Pharmicell, Valneva, Altimmune, Boiron and more.

Rigel Pharmaceuticals Overview

About Rigel Pharmaceuticals

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.


Founded

1996

HQ

United States

Employees

164

Website

rigel.com

Financials (LTM)

Revenue: $284M
EBITDA: $95M

EV

$456M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Rigel Pharmaceuticals Financials

Rigel Pharmaceuticals reported last 12-month revenue of $284M and EBITDA of $95M.

In the same LTM period, Rigel Pharmaceuticals generated $264M in gross profit, $95M in EBITDA, and $238M in net income.

Revenue (LTM)


Rigel Pharmaceuticals P&L

In the most recent fiscal year, Rigel Pharmaceuticals reported revenue of $294M and EBITDA of $132M.

Rigel Pharmaceuticals is profitable as of last fiscal year, with gross margin of 93%, EBITDA margin of 45%, and net margin of 125%.

See analyst estimates for Rigel Pharmaceuticals
LTMLast FY202320242025202620272028
Revenue$284M$294M$117M$179M$294M
Gross Profit$264M$275M$110M$161M$275M
Gross Margin93%93%94%90%93%
EBITDA$95M$132M($17M)$29M$132M
EBITDA Margin33%45%(15%)16%45%
EBIT Margin36%43%(18%)13%43%
Net Profit$238M$367M($25M)$17M$367M
Net Margin84%125%(21%)10%125%
Net Debt-$12M---

Financial data powered by Morningstar, Inc.

Rigel Pharmaceuticals Stock Performance

Rigel Pharmaceuticals has current market cap of $557M, and enterprise value of $456M.

Market Cap Evolution


Rigel Pharmaceuticals' stock price is $30.08.

Rigel Pharmaceuticals share price decreased by 1.3% in the last 30 days, and increased by 60.6% in the last year.

Rigel Pharmaceuticals has an EPS (earnings per share) of $19.84.

See more trading valuation data for Rigel Pharmaceuticals
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$456M$557M0.8%-1.3%11.2%60.6%$19.84

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Rigel Pharmaceuticals Valuation Multiples

Rigel Pharmaceuticals trades at 1.6x EV/Revenue multiple, and 4.8x EV/EBITDA.

See NTM and 2027E valuation multiples for Rigel Pharmaceuticals

EV / Revenue (LTM)


Rigel Pharmaceuticals Financial Valuation Multiples

As of June 3, 2026, Rigel Pharmaceuticals has market cap of $557M and EV of $456M.

Rigel Pharmaceuticals has a P/E ratio of 2.3x.

LTMLast FY202320242025202620272028
EV/Revenue1.6x1.5x3.9x2.5x1.5x
EV/EBITDA4.8x3.5x(26.8x)16.0x3.5x
EV/EBIT4.4x3.6x(22.2x)18.8x3.6x
EV/Gross Profit1.7x1.7x4.2x2.8x1.7x
P/E2.3x1.5x(22.2x)31.8x1.5x
EV/FCF-6.0x(22.0x)14.7x6.0x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Rigel Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Rigel Pharmaceuticals Margins & Growth Rates

Rigel Pharmaceuticals decreased revenue by 8% and EBITDA by 61% in the last fiscal year.

In the most recent fiscal year, Rigel Pharmaceuticals reported gross margin of 93%, EBITDA margin of 45%, and net margin of 125%.

See estimated margins and future growth rates for Rigel Pharmaceuticals

Rigel Pharmaceuticals Margins

Last FY202420252026202720282029
Gross Margin93%90%93%92%
EBITDA Margin45%16%45%19%
EBIT Margin43%13%43%27%
Net Margin125%10%125%23%
FCF Margin26%17%26%-

Rigel Pharmaceuticals Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(8%)53%64%(8%)
Gross Profit Growth(9%)46%71%(9%)
EBITDA Growth(61%)(268%)361%(61%)
EBIT Growth(42%)(218%)419%(42%)
Net Profit Growth(83%)(170%)1999%(83%)
FCF Growth-(250%)143%-

Data powered by FactSet, Inc. and Morningstar, Inc.

Rigel Pharmaceuticals Operational KPIs

Rigel Pharmaceuticals' revenue per employee in the last FY averaged $1.8M, while opex per employee averaged $0.9M for the same period.

Rigel Pharmaceuticals' Rule of 40 is 11% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Rigel Pharmaceuticals' Rule of X is (2%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Rigel Pharmaceuticals
LTMLast FY202320242025202620272028
Rule of 4037%11%---
Bessemer Rule of X43%(2%)---
Revenue per Employee-$1.8M---
Opex per Employee-$0.9M---
G&A Expenses to Revenue42%39%--39%
R&D Expenses to Revenue14%11%21%13%11%
Opex to Revenue-51%111%76%51%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Rigel Pharmaceuticals Competitors

Rigel Pharmaceuticals competitors include Pharmicell, Valneva, Altimmune, Boiron, Avalon Pharma, Gyre Therapeutics, enGene, Ironwood Pharmaceuticals, Nika Pharmaceuticals and Nxera Pharma.

Most Rigel Pharmaceuticals public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Pharmicell6.9x5.9x20.6x16.5x
Valneva3.3x3.5x(11.5x)(11.9x)
Altimmune6543.5x10372.9x(3.1x)(2.5x)
Boiron0.9x-7.0x-
Avalon Pharma4.7x4.5x16.8x15.6x
Gyre Therapeutics4.2x4.5x35.2x(170.9x)
enGene----
Ironwood Pharmaceuticals3.1x2.5x6.6x4.3x

This data is available for Pro users. Sign up to see all Rigel Pharmaceuticals competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Rigel Pharmaceuticals

When was Rigel Pharmaceuticals founded?Rigel Pharmaceuticals was founded in 1996.
Where is Rigel Pharmaceuticals headquartered?Rigel Pharmaceuticals is headquartered in United States.
How many employees does Rigel Pharmaceuticals have?As of today, Rigel Pharmaceuticals has over 164 employees.
Who is the CEO of Rigel Pharmaceuticals?Rigel Pharmaceuticals' CEO is Raul R. Rodriguez.
Is Rigel Pharmaceuticals publicly listed?Yes, Rigel Pharmaceuticals is a public company listed on Nasdaq.
What is the stock symbol of Rigel Pharmaceuticals?Rigel Pharmaceuticals trades under RIGL ticker.
When did Rigel Pharmaceuticals go public?Rigel Pharmaceuticals went public in 2000.
Who are competitors of Rigel Pharmaceuticals?Rigel Pharmaceuticals main competitors include Pharmicell, Valneva, Altimmune, Boiron, Avalon Pharma, Gyre Therapeutics, enGene, Ironwood Pharmaceuticals, Nika Pharmaceuticals, Nxera Pharma.
What is the current market cap of Rigel Pharmaceuticals?Rigel Pharmaceuticals' current market cap is $557M.
What is the current revenue of Rigel Pharmaceuticals?Rigel Pharmaceuticals' last 12 months revenue is $284M.
What is the current revenue growth of Rigel Pharmaceuticals?Rigel Pharmaceuticals revenue growth (NTM/LTM) is 4%.
What is the current EV/Revenue multiple of Rigel Pharmaceuticals?Current revenue multiple of Rigel Pharmaceuticals is 1.6x.
What is the current EBITDA of Rigel Pharmaceuticals?Rigel Pharmaceuticals' last 12 months EBITDA is $95M.
What is Rigel Pharmaceuticals' EBITDA margin?Rigel Pharmaceuticals' last 12 months EBITDA margin is 33%.
What is the current EV/EBITDA multiple of Rigel Pharmaceuticals?Current EBITDA multiple of Rigel Pharmaceuticals is 4.8x.
How many companies Rigel Pharmaceuticals has acquired to date?Rigel Pharmaceuticals hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Rigel Pharmaceuticals has invested to date?Rigel Pharmaceuticals hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Rigel Pharmaceuticals

Lists including Rigel Pharmaceuticals

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial